Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer

References

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495 - 497
   PubMed Web of Science ®Google Scholar
• Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 2009; 18:81 - 100
   PubMedGoogle Scholar
• Natarajan A, Xiong CY, Gruettner C, DeNardo GL, DeNardo SJ. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. Cancer Biother Radiopharm 2008; 23:82 - 91
   PubMed Web of Science ®Google Scholar
• Sachdeva MS. Drug targeting systems for cancer chemotherapy. Expert Opin Investig Drugs 1998; 7:1849 - 1864
   PubMedGoogle Scholar
• Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006; 5:1909 - 1917
   PubMed Web of Science ®Google Scholar
• Stewart Bak P. World Cancer Report 2003; World Health Organization
   Google Scholar
• Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94:15 - 21
   PubMed Web of Science ®Google Scholar
• Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008; 34:592 - 602
   PubMed Web of Science ®Google Scholar
• Liu X, Wang X, Wei D, Cai M, Li G. [Internalization of antibody-targeted immunonanoparticles into human hepatoma cells and its reversal effect on MDR]. Sichuan Da Xue Xue Bao Yi Xue Ban 2003; 34:431 - 434
   PubMedGoogle Scholar
• Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008; 58:97 - 110
   PubMed Web of Science ®Google Scholar
• Pietersz GA, Kanellos J, Smyth MJ, Zalcberg J, McKenzie IF. The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer. Immunol Cell Biol 1987; 65:111 - 125
   PubMed Web of Science ®Google Scholar
• Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006; 23:1417 - 1450
   PubMed Web of Science ®Google Scholar
• Walker B Jr, Mouton CP. Nanotechnology and nanomedicine: a primer. J Natl Med Assoc 2006; 98:1985 - 1988
   PubMed Web of Science ®Google Scholar
• National Nanotechnology Initiative 2010; www.nano.gov/
   Google Scholar
• Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 2007; 150:552 - 558
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19:311 - 330
   PubMed Web of Science ®Google Scholar
• Poole CP. Introduction to Nanotechnology 2003; Hoboken, New Jersey John Wiley and Sons
   Google Scholar
• Hassan M. Nanotechnology. Science 2004; 304:1732 - 1734
   PubMed Web of Science ®Google Scholar
• Webster TJ. Nanomedicine: what's in a definition?. Int J Nanomedicine 2006; 1:115 - 116
   PubMed Web of Science ®Google Scholar
• Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004; 429:629 - 635
   PubMed Web of Science ®Google Scholar
• De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008; 3:133 - 149
   PubMed Web of Science ®Google Scholar
• Jain KK. Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 2005; 4:645 - 650
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007; 9:128 - 147
   PubMed Web of Science ®Google Scholar
• de Silva MN. Nanotechnology and nanomedicine: a new horizon for medical diagnostics and treatment. Arch Soc Esp Oftalmol 2007; 82:331 - 334
   PubMedGoogle Scholar
• Polakis P. Arming antibodies for cancer therapy. Curr Opin Pharmacol 2005; 5:382 - 387
   PubMed Web of Science ®Google Scholar
• Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21:778 - 784
   PubMed Web of Science ®Google Scholar
• Kaneko T, Willner D, Monkovic I, Knipe JO, Braslawsky GR, Greenfield RS, et al. New hydrazone derivatives of adriamycin and their immunoconjugates—a correlation between acid stability and cytotoxicity. Bioconjug Chem 1991; 2:133 - 141
   PubMed Web of Science ®Google Scholar
• Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002; 13:40 - 46
   PubMed Web of Science ®Google Scholar
• Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005; 11:843 - 852
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Etrych T, Chytil P, Jelinkova M, Rihova B. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J Drug Target 2004; 12:477 - 489
   PubMed Web of Science ®Google Scholar
• Xia CF, Boado RJ, Pardridge WM. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm 2009; 6:747 - 751
   PubMed Web of Science ®Google Scholar
• Xia CF, Zhang Y, Boado RJ, Pardridge WM. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 2007; 24:2309 - 2316
   PubMed Web of Science ®Google Scholar
• Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2010; 2:14
   PubMedGoogle Scholar
• Greenwald RB. PEG drugs: an overview. J Control Release 2001; 74:159 - 171
   PubMed Web of Science ®Google Scholar
• John R, Rezaeipoor R, Adie SG, Chaney EJ, Oldenburg AL, Marjanovic M, et al. In vivo magnetomotive optical molecular imaging using targeted magnetic nanoprobes. Proc Natl Acad Sci USA 2010; 107:8085 - 8090
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4:145 - 160
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005; 16:691 - 707
   PubMed Web of Science ®Google Scholar
• Zhong YQ, Wei J, Fu YR, Shao J, Liang YW, Lin YH, et al. [Toxicity of cationic liposome Lipofectamine 2000 in human pancreatic cancer Capan-2 cells]. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28:1981 - 1984
   PubMedGoogle Scholar
• Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55:3752 - 3756
   PubMed Web of Science ®Google Scholar
• Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 2003; 8:396 - 403
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004; 15:517 - 525
   PubMed Web of Science ®Google Scholar
• Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release 2008; 126:50 - 58
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997; 36:66 - 75
   PubMed Web of Science ®Google Scholar
• Crosasso P, Brusa P, Dosio F, Arpicco S, Pacchioni D, Schuber F, et al. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. J Pharm Sci 1997; 86:832 - 839
   PubMed Web of Science ®Google Scholar
• Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996; 93:14164 - 14169
   PubMed Web of Science ®Google Scholar
• Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 1999; 10:2941 - 2952
   PubMed Web of Science ®Google Scholar
• Pan X, Wu G, Yang W, Barth RF, Tjarks W, Lee RJ. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem 2007; 18:101 - 108
   PubMed Web of Science ®Google Scholar
• Rawat M, Singh D, Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull 2006; 29:1790 - 1798
   PubMed Web of Science ®Google Scholar
• Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17:1263 - 1268
   PubMed Web of Science ®Google Scholar
• Li C. Poly(L-glutamic acid)—anticancer drug conjugates. Adv Drug Deliv Rev 2002; 54:695 - 713
   PubMed Web of Science ®Google Scholar
• Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008; 99:392 - 397
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14:1310 - 1316
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794 - 7803
   PubMed Web of Science ®Google Scholar
• Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2:347 - 360
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound nanoparticle paclitaxel. Clin Adv Hematol Oncol 2005; 3:348 - 349
   PubMedGoogle Scholar
• Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005; 23:7785 - 7793
   PubMed Web of Science ®Google Scholar
• Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem 2008; 19:2321 - 2331
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu X, Chen L, Cheng D, Rusckowski M, Hnatowich DJ. Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. Eur J Nucl Med Mol Imaging 2009; 36:1977 - 1986
   PubMed Web of Science ®Google Scholar
• Fujita M, Lee BS, Khazenzon NM, Penichet ML, Wawrowsky KA, Patil R, et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid). J Control Release 2007; 122:356 - 363
   PubMed Web of Science ®Google Scholar
• Huang KH, Liu JH, Wang LY, Zhu ZH, Chen QK, Min J, et al. [Study of the anti-tumor effect of anti-vascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles]. Zhonghua Wei Chang Wai Ke Za Zhi 2007; 10:482 - 485
   PubMedGoogle Scholar
• Nobs L, Buchegger F, Gurny R, Allemann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem 2006; 17:139 - 145
   PubMed Web of Science ®Google Scholar
• Kos J, Obermajer N, Doljak B, Kocbek P, Kristl J. Inactivation of harmful tumour-associated proteolysis by nanoparticulate system. Int J Pharm 2009; 381:106 - 112
   PubMed Web of Science ®Google Scholar
• Lin HY, Landersdorfer CB, London D, Meng R, Lim CU, Lin C, et al. Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. PLoS Comput Biol 2011; 7:1001073
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Dorodnych TY, Klinskii EY, Kliushnenkova EN, Shemchukova OB, Goncharova ON. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br J Cancer 1996; 74:1545 - 1552
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release 2001; 74:295 - 302
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65:271 - 284
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41:189 - 207
   PubMedGoogle Scholar
• Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46:169 - 185
   PubMed Web of Science ®Google Scholar
• Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001; 74:47 - 61
   PubMed Web of Science ®Google Scholar
• Roby A, Erdogan S, Torchilin VP. Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur J Pharm Biopharm 2006; 62:235 - 240
   PubMed Web of Science ®Google Scholar
• Liao C, Sun Q, Liang B, Shen J, Shuai X. Targeting EGFR-overexpressing tumor cells using Cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide. Eur J Radiol 2010; In press
   Web of Science ®Google Scholar
• Sharma P, Brown S, Walter G, Santra S, Moudgil B. Nanoparticles for bioimaging. Adv Colloid Interface Sci 2006; 123–126:471 - 485
   PubMed Web of Science ®Google Scholar
• Shim SY, Woo JR, Nam EJ, Hong HJ, Mook-Jung I, Kim YH, et al. Stepwise silver-staining-based immunosorbent assay for amyloid-beta autoantibody detection. Nanomedicine 2008; 3:485 - 493
   PubMed Web of Science ®Google Scholar
• Roca M, Haes AJ. Probing cells with noble metal nanoparticle aggregates. Nanomedicine 2008; 3:555 - 565
   PubMed Web of Science ®Google Scholar
• Kawano T, Yamagata M, Takahashi H, Niidome Y, Yamada S, Katayama Y, et al. Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses. J Control Release 2006; 111:382 - 389
   PubMed Web of Science ®Google Scholar
• Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, Kawano T, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release 2006; 114:343 - 347
   PubMed Web of Science ®Google Scholar
• Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005; 1:325 - 327
   PubMed Web of Science ®Google Scholar
• Shenoy D, Fu W, Li J, Crasto C, Jones G, DiMarzio C, et al. Surface functionalization of gold nanoparticles using hetero-bifunctional poly(ethylene glycol) spacer for intracellular tracking and delivery. Int J Nanomedicine 2006; 1:51 - 57
   PubMed Web of Science ®Google Scholar
• Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 2008; 4:273 - 382
   PubMed Web of Science ®Google Scholar
• Melancon MP, Lu W, Yang Z, Zhang R, Cheng Z, Elliot AM, et al. In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol Cancer Ther 2008; 7:1730 - 1739
   PubMed Web of Science ®Google Scholar
• Curley SA, Cherukuri P, Briggs K, Patra CR, Upton M, Dolson E, et al. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J Exp Ther Oncol 2008; 7:313 - 326
   PubMedGoogle Scholar
• Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 2008; 68:1970 - 1978
   PubMed Web of Science ®Google Scholar
• Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 2005; 9:674 - 679
   PubMed Web of Science ®Google Scholar
• Ashcroft JM, Tsyboulski DA, Hartman KB, Zakharian TY, Marks JW, Weisman RB, et al. Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody. Chem Commun 2006; 3004 - 3006
   PubMed Web of Science ®Google Scholar
• Pastorin G, Wu W, Wieckowski S, Briand JP, Kostarelos K, Prato M, et al. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun 2006; 1182 - 1184
   PubMed Web of Science ®Google Scholar
• Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, Briand JP, et al. Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed Engl 2005; 44:6358 - 6362
   PubMed Web of Science ®Google Scholar
• Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008; 41:60 - 68
   PubMed Web of Science ®Google Scholar
• Yang H, Liu C, Yang D, Zhang H, Xi Z. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. J Appl Toxicol 2009; 29:69 - 78
   PubMed Web of Science ®Google Scholar
• Donaldson K, Aitken R, Tran L, Stone V, Duffin R, Forrest G, et al. Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol Sci 2006; 92:5 - 22
   PubMed Web of Science ®Google Scholar
• Shvedova AA, Castranova V, Kisin ER, Schwegler-Berry D, Murray AR, Gandelsman VZ, et al. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health A 2003; 66:1909 - 1926
   PubMed Web of Science ®Google Scholar
• Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 2002; 99:12617 - 12621
   PubMed Web of Science ®Google Scholar
• Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug Chem 2004; 15:79 - 86
   PubMed Web of Science ®Google Scholar
• Nurunnabi M, Cho KJ, Choi JS, Huh KM, Lee YK. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials 2010; 31:5436 - 5444
   PubMed Web of Science ®Google Scholar
• McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 2007; 48:1180 - 1189
   PubMed Web of Science ®Google Scholar
• Ma J, Fan Q, Wang L, Jia N, Gu Z, Shen H. Synthesis of magnetic and fluorescent bifunctional nanocomposites and their applications in detection of lung cancer cells in humans. Talanta 2010; 81:1162 - 1169
   PubMed Web of Science ®Google Scholar
• Carpin LB, Bickford LR, Agollah G, Yu TK, Schiff R, Li Y, et al. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res Treat 2010; 125:27 - 34
   PubMed Web of Science ®Google Scholar
• Kikumori T, Kobayashi T, Sawaki M, Imai T. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res Treat 2009; 113:435 - 441
   PubMed Web of Science ®Google Scholar
• Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 2005; 57:637 - 651
   PubMed Web of Science ®Google Scholar
• Marschall AL, Frenzel A, Schirrmann T, Schungel M, Dubel S. Targeting antibodies to the cytoplasm. MAbs 2011; 3:3 - 16
   PubMed Web of Science ®Google Scholar
• Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55:1189 - 1193
   PubMed Web of Science ®Google Scholar
• Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88:223 - 233
   PubMed Web of Science ®Google Scholar
• Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 1991; 88:1864 - 1868
   PubMed Web of Science ®Google Scholar
• Liu X, Wang Y, Nakamura K, Kubo A, Hnatowich DJ. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery. Cancer Gene Ther 2008; 15:126 - 132
   PubMed Web of Science ®Google Scholar
• Yang H, Wu Q, Tang M, Liu X, Deng H, Kong L, et al. In vitro study of silica nanoparticle-induced cytotoxicity based on real-time cell electronic sensing system. J Nanosci Nanotechnol 10:561 - 568
   PubMed Web of Science ®Google Scholar
• Kneuer C, Sameti M, Bakowsky U, Schiestel T, Schirra H, Schmidt H, et al. A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro. Bioconjug Chem 2000; 11:926 - 932
   PubMed Web of Science ®Google Scholar
• Julien DC, Richardson CC, Beaux MF 2nd, McIlroy DN, Hill RA. In vitro proliferating cell models to study cytotoxicity of silica nanowires. Nanomedicine 2010; 6:84 - 92
   PubMed Web of Science ®Google Scholar
• Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113:823 - 839
   PubMed Web of Science ®Google Scholar
• Ye Y, Liu J, Xu J, Sun L, Chen M, Lan M. Nano-SiO2 induces apoptosis via activation of p53 and Bax mediated by oxidative stress in human hepatic cell line. Toxicol In Vitro 24:751 - 758
   PubMed Web of Science ®Google Scholar
• Chen TJ, Cheng TH, Chen CY, Hsu SC, Cheng TL, Liu GC, et al. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 2009; 14:253 - 260
   PubMed Web of Science ®Google Scholar
• Chiu SJ, Ueno NT, Lee RJ. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release 2004; 97:357 - 369
   PubMed Web of Science ®Google Scholar
• Cirstoiu-Hapca A, Bossy-Nobs L, Buchegger F, Gurny R, Delie F. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Int J Pharm 2007; 331:190 - 196
   PubMed Web of Science ®Google Scholar
• Choi D, McIlroy D, Nagler J, Aston E, Hrdlicka P, Gustin K, et al. Kumar SSR. One-dimensional silica structures and their applications to the biological sciences. Nanostructured Oxides for Life Sciences 2009; 3:Wiley-VCH 83 - 108
   Google Scholar